Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.56 |
| ▸ | MMP2 | P08253 | 9/20 | 0.56 |
| ▸ | MMP9 | P14780 | 9/20 | 0.56 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SI | P14410 | 1/20 | 0.47 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8839724 | 0.74 | MMP9 (0.94) | NR3C1MMP2MMP9KCNA5KMT2A | |
| SCHEMBL27701629 | 0.74 | NR3C1 (0.55) | NR3C1MMP2MMP9MGAMGAA | |
| SCHEMBL27701630 | 0.74 | NR3C1 (0.55) | NR3C1MMP2MMP9MGAMGAA | |
| SCHEMBL1287300 | 0.74 | MAPT (0.57) | GAAKCNA5KMT2AMEN1L3MBTL1 | |
| SCHEMBL1287270 | 0.74 | MAPT (0.57) | GAAKCNA5KMT2AMEN1L3MBTL1 | |
| SCHEMBL6769966 | 0.73 | CYP1A2 (0.45) | MMP2MMP9GAAPOLB | |
| SCHEMBL698227 | 0.73 | KMT2A (0.46) | MMP2MMP9KCNA5KMT2AMEN1 | |
| Acetic Acid SCHEMBL697092 | 0.72 | ALOX12 (0.66) | NR3C1MMP2MMP9KCNA5 | |
| SCHEMBL3134137 | 0.72 | NR3C1 (1.00) | NR3C1MMP2MMP9PGRNR3C2 | |
| SCHEMBL7386419 | 0.72 | MMP9 (1.00) | NR3C1MMP2MMP9KCNA5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423190-A1 | Compounds Exhibiting PGD 2 Receptor Antagonism | Shionogi&Co., Ltd. (JP) | 2012-02-29 | — | — | EP | claimed |
| US-20090258922-A1 | COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST | SHIONOGI & CO., LTD. | 2009-10-15 | — | — | US | claimed |
| US-20050171143-A1 | Compound exhibiting pgd 2 receptor antagonism | SHIONOGI & CO., LTD. (JP) | 2005-08-04 | — | — | US | claimed |
| EP-1505061-A1 | COMPOUND EXHIBITING PGD 2 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2005-02-09 | — | — | EP | claimed |
| EP-2423190-A1 | Compounds Exhibiting PGD 2 Receptor Antagonism | Shionogi&Co., Ltd. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20090258922-A1 | COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST | SHIONOGI & CO., LTD. | 2009-10-15 | — | — | US | disclosed |
| US-7534897-B2 | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism | SHIONOGI & CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20050171143-A1 | Compound exhibiting pgd 2 receptor antagonism | SHIONOGI & CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1505061-A1 | COMPOUND EXHIBITING PGD 2 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2005-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258922-A1 | COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST | CYSLTR2, CYSLTR1, HRH2 | NR3C1 75/4885MMP2 3413/4885MMP9 3515/4885 |
| US-20050171143-A1 | Compound exhibiting pgd 2 receptor antagonism | CYSLTR2, CYSLTR1, HRH2 | NR3C1 76/4885MMP2 4092/4885MMP9 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.